Gene therapy · Gene replacement · developed by UniQure Biopharma B.V.
Alipogene tiparvovec (Glybera) is a gene therapy delivered by intramuscular injection at a dose of 1x10^12 gc/kg. It is studied in lipoprotein lipase (LPL) deficiency, also classed as hyperlipoproteinemia type I.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02904772 | Phase 2 | LPL Deficiency | Withdrawn | QURE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
LPL Deficiency
Updated Oct 25, 2026. Something wrong or missing? Report it on the QURE page.
See QURE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
QURE catalysts and pipeline →